Updated from 11:27 a.m. EDT

While investors around the world are fearful of a potential global depression, strategic value-additive acquisitions are bountiful across a wide array of sectors and businesses. Large-capitalized companies are finally using their stockpiles of cash and the recent decline in the world markets to bolster their business lines, picking up companies that they think are cheaply valued.

Strategic mergers are flying all over this depressed market, and the biotechnology space is no exception.

On Monday, the Wall Street Journal reported that Genentech's ( DNA) board of directors is close to striking a $95-per-share sale to Roche, and Dow Chemical ( DOW) and Rohm & Hass ( ROH) have agreed to a takeover agreement in which Rohm & Hass shareholders will receive $78 per share.

On Monday morning, Merck ( MRK) offered to acquire Schering-Plough ( SGP) for $41.1 billion, and CF Industries ( CF) rejected Agrium's ( AGU) offer to acquire the company. Pfizer's ( PFE) purchase of Wyeth ( WYE) has also been getting a lot of attention.

This is one of the most active sectors for mergers and acquisitions right now and one of the best places for making money in these uncertain markets.

To read more, visit Stockpickr.com.

Who's on Stockpickr Answers next? David MacDougall will be on Stockpickr Answers on Tuesday, March 10 to respond to investing and trading questions posed by members of the Stockpickr community. Not a member? Join the Stockpickr community today -- free.
Stockpickr is a wholly owned subsidiary of TheStreet.com.